Hyperbaric Oxygen Therapy — Coverage Criteria for Systemic HBOT; Topical HBOT Investigational
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines BCBSNC coverage and medical necessity criteria for systemic hyperbaric oxygen therapy (HBOT) across listed indications; topical HBOT is considered investigational and excluded from coverage; applies to BCBSNC members and providers requesting payment/authorization for HBOT services.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Covered Indications (systemic HBOT)
Systemic hyperbaric oxygen therapy is covered when the condition is one of the listed indications and any condition-specific criteria are met.
See UHMS 2023 indications and policy details for condition-specific guidance.
Wagner grade threshold and standard therapy duration specified in diabetic wound criteria.
Diabetic lower-extremity wound — Initial therapy
Covered for non-healing diabetic lower-extremity wounds when ALL of the following are met:
Society of Vascular Surgery/other guideline language supports adjunctive HBOT for ulcers failing to improve after a minimum of 4 weeks (30 days) and UHMS suggests adding HBOT for Wagner grade 3+ not showing significant improvement after 30 days.
Evidence-based coverage conclusions for listed non-wound indications
For several non-wound indications referenced in the evidence summary, the policy finds insufficient evidence:
Cochrane review pooled 3 of 11 trials showing short-term relief.
Adverse events reported include radiation tissue injury and seizures.
Topical hyperbaric oxygen therapy is investigational for all indications and is expressly excluded from coverage by BCBSNC. Requests for topical HBOT will be denied as investigational.
Hyperbaric oxygen therapy that is not one of the listed covered systemic indications is considered investigational/not medically necessary. Per policy language, HBOT is investigational for all other conditions not listed in the covered indications.
The policy distinguishes topical hyperbaric oxygen therapy from systemic hyperbaric pressurization. Historic policy language specifies that topical HBOT is not considered hyperbaric oxygen pressurization and has been treated separately in prior revisions.
Use of topical HBOT or systemic HBOT for indications not specifically listed as covered is considered investigational / not medically necessary under this policy. Coverage is limited to the systemic HBOT indications explicitly enumerated in the policy.
Historically, the policy has listed numerous non-covered or investigational indications as examples of therapies not covered. Past updates added items such as autism spectrum disorders, early treatment to reduce radiation side effects, bisphosphonate-related osteonecrosis of the jaw, motor dysfunction after stroke, herpes zoster, vascular dementia, and other conditions to the non-covered/investigational lists.
Applicable Codes and Clinical Thresholds
Prior Authorization, Documentation, and Billing Guidance
Prior authorization required for systemic HBOT; topical HBOT not covered
Systemic hyperbaric oxygen therapy (HBOT) is covered when the medical necessity criteria for a listed indication are met; topical hyperbaric oxygen therapy is considered investigational and is not covered.
Applicable service codes — review and documentation may be required
The policy lists applicable service codes that may be subject to review; inclusion does not guarantee reimbursement and BCBSNC may request medical records to determine medical necessity for these services.
Step/sequence: HBOT only after adequate trial of standard wound therapy
For diabetic lower‑extremity (foot) ulcers, HBOT is an adjunctive therapy to be considered only after an adequate trial of standard wound therapy has failed to produce measurable improvement (guideline-specified 4 to 6 weeks or no measurable healing after 30 days).
- Standard therapy threshold in policy: no measurable signs of healing after 30 days of an adequate course of standard wound therapy
- Society of Vascular Surgery guideline: consider HBOT after minimum 4 weeks (or 4–6 weeks) of failed standard wound therapy
Required clinical documentation for diabetic foot ulcer coverage
Documentation to support coverage for diabetic lower‑extremity wounds must show the patient has type I or II diabetes, the wound is due to diabetes, the wound is Wagner grade 3 or higher, and there have been no measurable signs of healing after 30 days of an adequate course of standard wound therapy.
- Diagnosis of type I or type II diabetes
- Statement that the lower‑extremity wound is due to diabetes
- Wagner wound grade (grade 3 or higher required)
- Documentation of at least 30 days of adequate standard wound therapy with no measurable healing
Medical records and documentation requirements when requested
When BCBSNC requests medical records to determine medical necessity, include all specific clinical information needed for review; letters of support/explanation are helpful but are not sufficient unless they contain the required documented elements.
- Include objective wound assessments, Wagner grade, duration and details of prior standard wound therapy, and diabetes diagnosis/status
- Letters of support only sufficient if they include all required information for medical necessity determination
Topical HBOT requests denied — investigational
Requests for topical hyperbaric oxygen therapy will be denied as investigational; topical HBOT is not covered under this policy.
Medical record requests and denial risk if documentation absent
BCBSNC may request medical records to determine medical necessity; failure to provide the requested records or required documentation can lead to denial of the request.
Background and Evidence Summary
Hyperbaric oxygen therapy can be delivered either systemically or topically. Systemic HBOT involves enclosing the patient in a pressure chamber (monoplace or multiplace) and breathing oxygen at pressures greater than atmospheric so that oxygen is carried systemically. Topical HBOT delivers 100% oxygen directly to an open moist wound via an appliance that encloses the wound area at pressure slightly above atmospheric; it is considered a distinct therapy from systemic hyperbaric pressurization. Adverse events associated with pressurized systemic therapy include pressure-related barotrauma and oxygen toxicity, with an overall low estimated adverse event rate noted in the policy.
Evidence-based conclusions and supporting references
The policy evidence review references randomized trials, systematic reviews, and specialty society guidance; key conclusions informing coverage decisions include the following:
See individual condition summaries for details and citations.
UHMS position statements also noted insufficient evidence for topical HBOT for certain conditions.
Topical HBOT is considered investigational for all indications.
Definitions and Safety
Policy Revision Timeline
Original policy established (Hyperbaric Oxygen Pressurization).
Reaffirmed and list of experimental/investigative indications added.
Policy revised (unspecified changes recorded in August 1992).
Revised to combine local and national policies; added indication for patients post head/neck radiation requiring full mouth extraction and noted prophylactic HBOT after radiation as investigational.
Revised to state topical hyperbaric oxygen therapy is considered investigational; reaffirmed by MPAG.
Indications updated per BCBSA/TEC and consultant recommendations; compromised skin grafts/flaps and acute thermal burns listed as non-covered.
Specialty Matched Consultant Advisory Panel review added new sources; policy reaffirmed with no criteria changes.
Policy name changed from 'Hyperbaric Oxygen Pressurization' to 'Hyperbaric Oxygen Therapy'; description and references updated following consultant and medical director review.
References and Policy Guideline section updated; consultant review noted with no change to policy statement.
Regulatory status updated and terminology changed from 'patients' to 'individuals' in coverage criteria; references updated.
References and 'When covered' section updated to add avascular necrosis (aseptic osteonecrosis) as a covered indication per UHMS guidance; policy guidelines and reviews updated.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.